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Here we show that Doxil
s has minimal antitumour activity in the isolated limb perfusion (ILP) setting and its activity was not
enhanced by the addition of tumour necrosis factor (TNF). Doxil
s accumulation in tumour tissue was low and also not augmented
by TNF. In contrast, activity of free conventional doxorubicin was enhanced by TNF. We conclude that application of Doxil
s in a
TNF-based ILP is not a useful alternative to free conventional doxorubicin or melphalan.
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Isolated limb perfusion (ILP) provides an excellent tool in the
treatment of locally advanced tumours. During ILP, high local drug
concentrations are possible due to minimal leakage into the
systemic circulation, and the effect on vital organs is limited,
allowing high dosages to be used. We and others have demon-
strated that addition of tumour necrosis factor (TNF) to an ILP
with melphalan increased the tumour response dramatically as
compared to melphalan alone (Lienard et al, 1992; Eggermont et al,
1996).
Melphalan is used most commonly in ILP, but other agents have
been applied with varying success in limb or organ perfusion
(Rossi et al, 1992; Weksler et al, 1994; Abolhoda et al, 1997). We
observed in ILP that local toxicity was dose-limiting at suboptimal
doxorubicin concentrations (Van Der Veen et al, 2000).
The formulation of doxorubicin in long-circulating liposomes
(Stealth liposomal doxorubicin, Doxil
s) prolongs circulation time,
decreases toxicity and augments localisation in tumour tissue
(Gabizon et al, 2003). We hypothesised that the use of Doxil
s in
ILP may reduce local toxicity while augmenting tumour accumula-
tion and improving tumour response. In this study, we examined
the efficacy of Doxil
s in a TNF-based ILP in sarcoma-bearing rats.
MATERIALS AND METHODS
Chemicals
Human recombinant TNF-a was kindly provided by Dr G Adolf
(Bender Wien GmbH, Wien, Austria). Pegylated liposomal
doxorubicin (Doxil
s, Caelyxt) was kindly provided by Dr
Working (ALZA Corporation, Mountain View, CA, USA). Doxor-
ubicin hydrochloride (adriblastina) was purchased from Pharma-
cia (Brussels, Belgium).
Animals and tumour model
Male inbred BN rats (soft-tissue sarcoma model, BN175) and
WAG/RIJ rats (osteosarcoma model, ROS-1) were obtained from
Harlan-CPB (Austerlitz, the Netherlands). Small fragments (3mm)
of tumour were implanted subcutaneously in the right hindleg, as
previously described (de Wilt et al, 1999). Tumour growth was
recorded by calliper measurements, and tumour volume was
calculated using the formula 0.4(A
2B) (where B represents the
largest diameter and A the diameter perpendicular to B). All
animal studies were done in accordance with protocols approved
by the Animal Care Committee of the Erasmus University
Rotterdam, the Netherlands (Workman et al, 1998).
A tumour response indicates either a partial remission (PR,
decrease of tumour volume between –25 and 90%) or a complete
remission (CR, tumour volume less than 10% of initial volume).
Isolated limb perfusion protocol
Rat limbs were perfused as previously described (de Wilt et al,
1999). Tumour necrosis factor (50mg), Doxil
s or doxorubicin
(400mg BN175 and 200mg ROS-1) were added as boluses to the
oxygenation reservoir. Control rats were perfused with Haemaccel
or placebo liposomes alone. The concentration of TNF was adapted
from previous animal studies, and doxorubicin concentrations that
yielded no local toxicity were used. All animal studies were
approved as stated above (Workman et al, 1998).
Assessment of doxorubicin accumulation in solid tumour
during ILP
Accumulation of doxorubicin in tumour and muscle was
determined directly after ILP, as previously described (Mayer
et al, 1989; Van Der Veen et al, 2000). As the ILP included a
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sthorough washout, there was no intravascular doxorubicin
present. All animal studies were approved as stated above
(Workman et al, 1998).
Statistical analysis
The results were evaluated for statistical significance using the
Mann–Whitney U-test with SPSS for Windows. P-values below
0.05 were considered statistically significant.
RESULTS
Tumour response to Doxil
s in TNF-based ILP Perfusion with
Doxil
s, TNF or buffer alone resulted in progressive disease in all
soft-tissuesarcoma-bearingrats (Figure1A).PerfusionwithDoxil
s
plus TNF resulted in a short growth delay followed by rapid
outgrowth of the tumour, and all rats showed progressive disease.
Application of free conventional doxorubicin resulted only in a
slight inhibition of the tumour growth, and no rats showed a
tumour response. Isolated limb perfusion with conventional
doxorubicin combined with 50mg TNF increased the antitumour
activity with a response rate of 83% (PR and CR combined)
(Po0.01 compared with doxorubicin alone).
Isolated limb perfusion in osteosarcoma-bearing rats with buffer
or conventional doxorubicin alone had no significant effect on
tumour growth (Figure 1B). Isolated limb perfusion with TNF
alone resulted in a response rate of 25%. Isolated limb perfusion
with conventional doxorubicin combined with TNF further
increased the tumour response to 83% (Po0.05 compared with
TNF alone or doxorubicin alone). Isolated limb perfusion with
Doxil
s only, induced slight tumour growth delay comparable to
free conventional doxorubicin. Strikingly, ILP with Doxil
s plus
TNF diminished the tumour response, and none of the rats showed
a tumour response.
Accumulation of doxorubicin in solid tumour after ILP
We observed that addition of TNF did not significantly augment
the accumulation of Doxil
s in soft-tissue sarcoma or osteosarco-
ma when compared to ILP with Doxil
s alone (data not shown).
Levels of doxorubicin were significantly increased when TNF was
added to ILP with free doxorubicin (Van Der Veen et al, 2000).
DISCUSSION
In the present study, we demonstrated that ILP treatment with
Doxil
s combined with TNF in sarcoma-bearing rats does not
provide a useful alternative to free conventional doxorubicin. The
lack of efficacy of Doxil
s is not due to failure of the drug to be
active at the tumour site, as dramatic synergy between Doxil
s and
TNF after systemic treatment has been shown (ten Hagen et al,
2000). Rather, we speculate that the liposomes are unable to
extravasate into the tumours during the relatively short ILP
interval.
In spite of the indicated usefulness of doxorubicin in ILP for the
treatment of sarcoma, we and others observed dose-limiting local
toxicity after a TNF-based ILP with conventional doxorubicin (Di
Filippo et al, 1999; Van Der Veen et al, 2000). Biodistribution and
pharmacokinetic studies with Doxil
s demonstrated a favourable
profile of the liposomal formulations over the free drugs, that is,
circulation time was extended, toxicity reduced and tumour
localisation was increased (Gabizon et al, 2003). Therefore, we
envisioned that Doxil
s could be a good alternative to free
conventional doxorubicin in ILP. However, Doxil
s failed to
induce any response in sarcoma-bearing rats, even when applied
in combination with TNF. Minimal accumulation of Doxil
s in
tumour after ILP with or without TNF was observed, whereas
considerably higher levels of doxorubicin were found in tumour
after ILP with free doxorubicin plus TNF. A possible explanation
for the difference in accumulation between free conventional
doxorubicin and liposomal doxorubicin is the particle size.
Whereas distribution of a small molecule like doxorubicin is
diffusion dependent, the transport of particulate matter is
convection dependent (Jain et al, 1990; Hobbs et al, 1998). This
would indicate that, during ILP, drug distribution is mostly
diffusion dependent and not convection dependent.
The increased tumour localisation of Doxil seen after systemic
administration is reportedly due to the ability of the pegylated
liposomes to avoid accumulation in the liver and spleen and other
parts of the mononuclear phagocytic system (MPS), which results
in a long circulation time and extravasation through the leaky
vasculature of tumours (Gabizon et al, 2003). The volume of
distribution of Doxil
s is markedly smaller than that of
doxorubicin given systemically, reflecting the broad tissue
distribution of the latter. The short 30-min circulation time
imposed by the ILP procedure is likely inadequate for the
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Figure 1 (A) Tumour volumes of subcutaneous implanted soft-tissue
sarcoma BN175 after isolated limb perfusion with perfusate alone (n¼6),
400mg Doxil
s (n¼4), 50mg TNF (n¼6), Doxil
s plus 50mg TNF (n¼8),
400mg free doxorubicin (DXR) (n¼7), or a combination of TNF and free
DXR (n¼6). (B) Tumour volumes of subcutaneous implanted osteosar-
coma ROS-1 after isolated limb perfusion with perfusate alone (n¼6),
200mg Doxil
s (n¼6), 50mg TNF (n¼8), 200mg Doxil
s plus 50mg TNF
(n¼7), 200mg free doxorubicin (DXR) (n¼6), or a combination of TNF
and DXR (n¼6). The mean tumour volumes are shown7s.e.
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scirculation time advantage of Doxil
s to have an effect on its
distribution, and, of course, the restriction of circulation to the
isolated limb obviates the value of avoiding the MPS. Thus, the
rapid distribution properties of the small doxorubicin molecule
makes it a better choice for ILP procedures, particularly when it is
used in combination with TNF.
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